Jefferies raises Azenta stock price target on growth outlook
Jefferies raised Azenta's (AZTA) price target to $52 from $44, citing strong Q4 results and 2027 growth outlook. The stock trades at $49.42, up 126% in six months. AZTA reported non-GAAP EPS of $0.28 vs. $0.12 estimate and revenue of $167M vs. $160.32M estimate. The company plans investments in multiomics and has $500M in cash.
How this was made
The 30-second read
Why it matters
The earnings beat and upgraded price target provide a clear catalyst for short‑term upside, while the cash‑rich balance sheet supports longer‑term confidence.
Market read
Azenta's earnings beat and higher guidance are fresh, material news that can move the stock and influence the genomics tools sector.
What to watch
Potential execution risk in scaling the multi‑omics business and integration of recent acquisitions.
Background
Azenta reported Q4 non‑GAAP EPS of $0.28 vs. $0.12 estimate and revenue of $167 M vs. $160.3 M estimate, with $500 M cash and a $118 M share buyback in H2 2026.
Ticker impact
Jefferies raised its price target to $52 and highlighted Azenta's Q4 earnings beat and 2027 guidance, indicating stronger growth and margin expansion.
likely upward pressure as investors price in higher guidance and improved cash position
The earnings beat and higher guidance are fresh information; the new $52 target provides a concrete catalyst for buying.
Market effects
Strong results may lift the broader life‑science tools sector as investors reassess growth prospects.
Positive for U.S. biotech and genomics stocks, with limited immediate global effect.
Modest; primarily influences U.S. small‑cap biotech investors.
Counterpoint
If the guidance proves overly optimistic, the stock could face a pull‑back once detailed execution plans are scrutinized.
Key entities
- companyAzenta, Inc.
Life‑science tools and services provider.
- analystJefferies
Equity research firm that raised the price target.
